ADC Therapeutics is raising $86.6M in a PIPE from existing investors as part of a strategic restructuring, extending its cash runway into 2029. Insider-led money is the tell — biotech tape rewards run

Strategic financial restructuring signals potential balance sheet changes for ADC Therapeutics.